RECORDATI UK LTD

1. RECORDATI UK LTD 2024-06-26 → present
2. EUSA PHARMA (UK) LIMITED 2015-03-23 → 2024-06-26
3. ESSEX BIDCO LIMITED 2014-11-26 → 2015-03-23

Values shown as filed in the company's annual accounts. — indicates the figure wasn't present under that line item in that period. About these numbers

Margins divide P&L lines by turnover. Gearing is liabilities over total assets. Current ratio is current assets over creditors falling due within one year. Interest cover is operating profit over absolute finance costs. Sector-distribution context coming next.

Accounting basis

FRS 102

Reporting scope

Standalone (parent only)

Auditor

Belluzzo Audit Limited

Audit opinion

Unqualified (clean)

Going concern

Affirmed

“The directors are required to prepare financial statements on the going concern basis, unless it is inappropriate to presume that the Company will continue in business. The directors believe that the adoption of the going concern basis for the preparation of the financial statements is appropriate as, based on current forecasts, the Company has enough funds to continue to trade and to meet their liabilities as and when they fall due for the foreseeable future and at least twelve months following the date of signing the financial statements of the Company for the year ended 31 December 2024.”

Group structure

1. RECORDATI UK LTD · parent
   1. Recordati Netherlands BV 100% · Netherlands · Pharmaceutical sales
   2. EUSA Pharma (CH) GmbH 100% · Switzerland · Pharmaceutical sales
   3. Recordati Korea, Ltd 100% · Korea · Pharmaceutical sales
   4. Recordati Argentina S.R.L 95% · Argentina · Pharmaceutical sales

Significant events

• “On the 26th of June 2024, the company changed its name from EUSA Pharma (UK) Limited to Recordati UK Limited following the passing of a Special Resolution duly filed at Companies House.”
• “The Company announced on 4 October 2024 an agreement with Sanofi to acquire the global rights to Enjaymo (sutimlimab), a biologic which is the only approved targeted product for the treatment of cold agglutinin disease (CAD), a rare B-cell lympho-proliferative disorder.”
• “EUSA Pharma Denmark, ApS was liquidates on 19 December 2023 and this resulted in a gain on disposal of €248k.”
• “In 2023, the Company sold three of its subsidiaries EUSA Pharma (France) to Recordati Rare Disease France EARL on 5 April 2023 for €4,909,000, SAS EUSA Pharma (US) LLC to Recordati Rare Disease Inc on 20 March 2023 for USD 35,000,000 and EUSA Pharma Iberia S.L. to Recordati Rare Disease Spain S.L. on 26 January 2023 for €3,428,078.”
• “In addition EUSA Pharma (Australia) Pty Ltd was deregistered on 10 April 2023.”

Auditor, going-concern and subsidiary information is drawn from the narrative of the latest annual accounts. About these numbers

Filings

4

last 12 months

Capital events

0

last 24 months

Officers appointed

1

last 12 months

Officers resigned

0

last 12 months

Direct counts from the register. No score, no rating — see the Filing timeline for the underlying events.

• Turnover

  +50.8%

  £129,897,712 → £195,863,384

• Cash

  +7.3%

  £2,067,441 → £2,218,273

• Net assets

  +4.6%

  £187,028,433 → £195,566,921

• Employees

  -15.8%

  76 → 64

• Operating profit

  +29%

  £45,432,559 → £58,600,902

• Profit before tax

  -31.6%

  £84,309,986 → £57,663,835

• Wages

  +8.8%

  £7,185,333 → £7,815,534

Each % is (latest − prior) ÷ |prior| for the line item as filed. The comparison is only shown when the latest and prior accounts cover broadly equal-length periods — short or long stubs (typical around incorporation or a year-end change) are suppressed rather than misrepresented. Lines a company doesn't report are omitted. About these numbers